Search details
1.
Inductively Coupled Plasma Mass SpectrometryâA Valid Method for the Characterization of Metal Conjugates in View of the Development of Radiopharmaceuticals.
Mol Pharm
; 20(4): 2150-2158, 2023 04 03.
Article
in English
| MEDLINE | ID: mdl-36826437
2.
Impact of the mouse model and molar amount of injected ligand on the tissue distribution profile of PSMA radioligands.
Eur J Nucl Med Mol Imaging
; 49(2): 470-480, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34402925
3.
Preclinical investigations using [177Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer.
Eur J Nucl Med Mol Imaging
; 49(11): 3639-3650, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35635566
4.
Preclinical Investigations to Explore the Difference between the Diastereomers [177Lu]Lu-SibuDAB and [177Lu]Lu-RibuDAB toward Prostate Cancer Therapy.
Mol Pharm
; 19(7): 2105-2114, 2022 07 04.
Article
in English
| MEDLINE | ID: mdl-35544699
5.
Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile.
Molecules
; 25(11)2020 May 29.
Article
in English
| MEDLINE | ID: mdl-32486054
6.
Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer.
Eur J Nucl Med Mol Imaging
; 46(9): 1919-1930, 2019 Aug.
Article
in English
| MEDLINE | ID: mdl-31134301
7.
Albumin-Binding and Conventional PSMA Ligands in Combination with 161Tb: Biodistribution, Dosimetry, and Preclinical Therapy.
J Nucl Med
; 64(10): 1625-1631, 2023 10.
Article
in English
| MEDLINE | ID: mdl-37442604
8.
Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancer.
NPJ Precis Oncol
; 7(1): 112, 2023 Nov 02.
Article
in English
| MEDLINE | ID: mdl-37919480
9.
[225Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [225Ac]Ac-PSMA-617.
Cancers (Basel)
; 14(22)2022 Nov 17.
Article
in English
| MEDLINE | ID: mdl-36428743
Results
1 -
9
de 9
1
Next >
>>